Bernd J. Schmitz‐Dräger

Author

Heinrich Heine University Düsseldorf ORCID

Also Known As

Arbeitskreis Prävention, Umwelt und komplementäre und alternative Medizin (AK KAM) von DGU und BDU, B J Schmitz-Dräger, B Schmitz-Draeger, B. J. Schmitz-Drager, B. J. Schmitz-Dräger, B. SCHMITZ-DRAGER, B. Schmitz-Draeger, B. Schmitz-Drager, B. Schmitz-Dräger, B.J. Schmitz-Draeger

209

Publications

4.6K

Citations

H-Index

Concepts

All Affiliations

Heinrich Heine University Düsseldorf Klinikum Fürth The University of Texas MD Anderson Cancer Center Friedrich-Alexander-Universität Erlangen-Nürnberg University of Southern California

About

Bernd J. Schmitz‐Dräger is an author at Heinrich Heine University Düsseldorf specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	23	1.6K
2	Cell Biology	4	4	310
3	Health Sciences	1	1	67
4	Public Health	1	1	35
5	Biochemistry	1	1	51

Bernd J. Schmitz‐Dräger

Publications

Citations

H-Index

Page 1

	Year	Citations
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers Vinata B. Lokeshwar, Tomonori Habuchi, H. Barton Grossman, Urology UrologyUrologic Cancer EpidemiologyGenitourinary CancerCancer DetectionMedicine	2005	426
DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinomas Andrea R. Florl, Roswitha Löwer, Bernd J. Schmitz‐Dräger, British Journal of Cancer	1999	251
Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers Tomonori Habuchi, Michael Marberger, Michael J. Droller, Urology Prognostic BiomarkersUrologyGenitourinary CancerMedicinePathology	2005	167
Expression of Basic Fibroblast Growth Factor in Primary Human Renal Tumors: Correlation With Poor Survival David M. Nanus, Bernd J. Schmitz‐Dräger, Robert J. Motzer, JNCI Journal of the National Cancer Institute Renal PathologyPathologyCell ProliferationNew YorkTumor Biology	1993	128
Treatment of High-grade Non–muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial “NIMBUS” Marc‐Oliver Grimm, Antoine G. van der Heijden, Marc Colombel, European Urology Urological ResearchUrologyBcg InstillationsUrologic Cancer EpidemiologyGenitourinary Cancer	2020	122
Hypomethylation of L1 LINE sequences prevailing in human urothelial carcinoma. Bjarne Jürgens, Bernd J. Schmitz‐Dräger, Wolfgang A. Schulz PubMed Epigenetic ChangeDna MethylationPathologyL1 Line SequencesCancer Biology	1996	114
Considerations on implementing diagnostic markers into clinical decision making in bladder cancer Yair Lotan, Shahrokh F. Shariat, Bernd J. Schmitz‐Dräger, Urologic Oncology Seminars and Original Investigations Prognostic BiomarkersUrologyGenitourinary CancerCancer DetectionCancer Screening	2010	105
Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study Tim M. Govers, Daphne Hessels, Virginie Vlaeminck‐Guillem, Prostate Cancer and Prostatic Diseases Comparative Modeling StudyUrologyHealth EconomicsMedicineEuropean Countries	2018	67
p53 immunohistochemistry in bladder cancer—a new approach to an old question Peter J. Goebell, Susan Groshen, Bernd J. Schmitz‐Dräger Urologic Oncology Seminars and Original Investigations Tumor BiologyUrological ResearchUrologyTumoral PathologyGenitourinary Cancer	2010	56
Loss of Heterozygosity at the NAD(P)H:Quinone Oxidoreductase Locus Associated with Increased Resistance against Mitomycin C in a Human Bladder Carcinoma Cell Line Peter Eickelmann, Wolfgang A. Schulz, D. Rohde, Biological Chemistry Hoppe-Seyler Oxidoreductase Locus AssociatedMitomycin CPathologyTumor BiologyOncology	1994	51

Page 1